Search results
AstraZeneca’s Truqap flops in Phase III triple negative breast cancer trial
Clinical Trials Arena via Yahoo Finance· 5 days agoAstraZeneca has been dealt a blow after its flagship breast cancer drug Truqap (capivasertib) did...
US Supreme Court Gives Pharma Companies a Chance to Thwart Terrorism-Funding Lawsuit
US News & World Report· 5 hours agoThe U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally ...
G1 Therapeutics' breast cancer drug fails in late-stage trial
Reuters· 8 hours agoG1 Therapeutics said on Monday its drug for a rare, aggressive form of breast cancer did not meet the main goal of overall survival in a late-stage trial.
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit
WSAU Wausau· 5 hours agoBy Mike Scarcella WASHINGTON (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge...
Britain snubs GSK in favour of US pharma giant for RSV vaccine
Daily Telegraph· 2 hours agoThe NHS has turned to US drugs giant Pfizer over its British rival GSK for vaccines against...
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
Zacks· 7 days agoAstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.
AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals
Morningstar· 7 days agoAstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its primary goals. The British-Swedish pharma ...
Data Science Hiring Process at AstraZeneca – AIM
Analytics India Magazine· 7 days agoWith over 45 years of presence in India, British-Swedish pharmaceutical and biotechnology giant AstraZeneca has data science and AI capabilities deeply ingrained across its ...
G1 Therapeutics' breast cancer drug fails in late-stage trial
Reuters via Yahoo News· 8 hours agoG1's drug trilaciclib was tested in 187 patients with metastatic triple-negative breast cancer, with the patients who took the drug showing a median overall survival of 17.4 months, while patients ...
Admiral Group And Two Other UK Exchange Stocks Estimated As Undervalued For Investment Consideration
Simply Wall St. via Yahoo Finance· 6 days agoThe United Kingdom's financial markets are currently poised at a critical juncture, with the FTSE...